Company: CORT
Filing Date: 2025-05-05
Form Type: 10-Q
Source: 0001628280-25-022173
Chunk: 3

Company: CORCEPT THERAPEUTICS INC
Filing Date: 2025-05-05
Form: 10-Q
Item: Part I, Item 1
Chunk 3
---
217)$543,735 $679,589 Issuance of common stock under incentive award plan1,712 1 12,899 — — — 12,900 Shares tendered to satisfy cost and statutory withholding requirements for net settlement of cashless option exercises and vesting of restricted stock(341)— — (21,086)— — (21,086)Repurchase of common stock in connection with Stock Repurchase Program(500)— — (27,433)— — (27,433)Stock-based compensation— — 15,687 — — — 15,687 Vesting of RSAs in connection with ESPP— — 2,172 — — — 2,172 Other comprehensive gain, net of tax— — — — 909 — 909 Net income— — — — — 20,547 20,547 Balance at March 31, 2025105,984 $137 $862,866 $(744,692)$692 $564,282 $683,285 

Common StockAdditional Paid-in CapitalTreasury StockAccumulated Other Comprehensive Income (Loss)Retained EarningsTotal Stockholders’ EquitySharesAmountBalance at December 31, 2023103,405 $133 $738,515 $(635,078)$609 $402,526 $506,705 Issuance of common stock under incentive award plan786 — 3,485 — — — 3,485 Shares tendered to satisfy cost and statutory withholding requirements for net settlement of cashless option exercises and vesting of restricted stock(143)— 2,032 (5,586)— — (3,554)Repurchase of common stock in connection with Stock Repurchase Program(20)— — (476)— — (476)Excise tax related to net share repurchases— — — 81 — — 81 Stock-based compensation— — 12,929 — — — 12,929 Vesting of RSAs in connection with ESPP— — 1,283 — — — 1,283 Other comprehensive loss, net of tax— — — — (351)— (351)Net income— —